

**Study Number:** R16011

**Test Type:** Teratology

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**C Number:**

**Study Gender:**

**PWG Approval Date**

**R13: Fetal Defect Cross Reference Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

R16011

Female

See web page for date of PWG Approval

**Date Report Requested:** 08/28/2019

**Time Report Requested:** 11:32:41

**Lab:** Southern Research

**Study Number:** R16011

**Test Type:** Teratology

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**R13: Fetal Defect Cross Reference Summary**  
**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine  
**CAS Number:** 95737-68-1

**Date Report Requested:** 08/28/2019

**Time Report Requested:** 11:32:41

**Lab:** Southern Research

---

**F0 Female**

---

**Treatment Groups (mg/kg/day)**

---

**0                      62.5                      125                      250                      500**

---

<b>Total number of fetuses examined</b>	<b>314</b>	<b>286</b>	<b>290</b>	<b>265</b>	<b>318</b>
<b>Total number of dams examined</b>	<b>23</b>	<b>20</b>	<b>21</b>	<b>20</b>	<b>22</b>

---

<b>Defect</b>	<b>Classification</b>	<b>Animal ID</b>			
---------------	-----------------------	------------------	--	--	--

---

**External**

---

<b>No. Fetuses Examined</b>	<b>314</b>	<b>286</b>	<b>290</b>	<b>265</b>	<b>318</b>
<b>No. Dams Examined</b>	<b>23</b>	<b>20</b>	<b>21</b>	<b>20</b>	<b>22</b>

**Body - General**

Body, Subcutaneous hemorrhage	Gross Finding	40(3)		79(12)
-------------------------------	---------------	-------	--	--------

**Extremities**

Tail, Thread-like	Malformation		73(4)	98(13)
-------------------	--------------	--	-------	--------

Study Number: R16011

Test Type: Teratology

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

R13: Fetal Defect Cross Reference Summary  
Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine  
CAS Number: 95737-68-1

Date Report Requested: 08/28/2019

Time Report Requested: 11:32:41

Lab: Southern Research

F0 Female

Treatment Groups (mg/kg/day)

0 62.5 125 250 500

Visceral

No. Fetuses Examined	314	286	290	265	318
No. Dams Examined	23	20	21	20	22

Abdominal Viscera

Liver lobe, left lateral, Additional fissure	Variation	26(14), 27(11), 28(3,7), 30(1), 44(14)	62(6), 66(11), 73(3,6)	87(13), 92(15)	106(2,5,6,7,8), 116(13,14)	
Liver lobe, left lateral, Discolored	Variation			76(9), 78(13,15), 79(6)		
Liver lobe, left lateral, Misshapen	Malformation				103(4)	
Liver lobe, left lateral, Supernumerary	Variation		28(6)	62(3), 73(6)		
Liver lobe, left medial, Additional fissure	Variation	1(12), 2(7), 16(7), 20(5)	26(7)	61(12)	102(9)	
Liver lobe, left medial, Discolored	Variation			53(3)	78(13)	101(2), 106(3,4)
Liver lobe, left medial, Misshapen	Malformation				101(2)	
Liver lobe, left medial, Supernumerary	Variation	1(16)	26(4), 30(3), 31(2), 50(5)	66(11)		
Liver lobe, right lateral, Supernumerary	Variation				116(5)	
Liver lobe, right medial, Additional fissure	Variation				106(6)	
Liver lobe, right medial, Supernumerary	Variation	16(14), 23(9), 24(12)		51(8)	88(6)	101(5)

Study Number: R16011

Test Type: Teratology

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

R13: Fetal Defect Cross Reference Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 08/28/2019

Time Report Requested: 11:32:41

Lab: Southern Research

F0 Female

Treatment Groups (mg/kg/day)

		0	62.5	125	250	500
Stomach, Hemorrhagic	Malformation				76(7), 92(7)	
<b>Heart</b>						
Aortic valve, Misshapen	Malformation	1(4), 3(10), 5(4), 7(1,10), 8(7), 9(6), 15(2), 18(2), 23(2)	27(10), 30(11,15), 31(3), 37(3), 46(11), 48(1,5), 49(6)	53(7), 56(13), 58(13), 60(7), 74(3)	78(9), 79(2,13), 81(4), 84(7,11), 86(9), 88(3), 94(3,9)	104(1,4), 116(10), 118(12), 122(1)
<b>Major Vessels</b>						
Aortic arch, Retroesophageal	Malformation				82(14)	
Innominate artery, Absent	Variation	2(3), 4(6), 8(6), 12(8), 13(1), 15(13), 16(2,4,5,16), 24(8,14), 25(3)	26(4), 31(10,14), 33(6), 35(1), 43(15), 46(1), 50(11,12)	51(1), 53(6), 56(1), 58(6,10), 59(13), 62(2), 69(2), 74(2,11), 75(14)	82(1,7), 84(4,11,12), 86(11), 97(9), 98(1,4)	101(6), 103(10), 114(10), 116(2), 120(4), 125(4,9)
Innominate artery, Short	Variation	2(1), 14(15), 18(5), 20(3), 22(15)	33(4,10), 48(9)	66(1), 69(4)	80(14), 84(1,6), 92(2)	109(6), 110(14), 116(11), 120(13)
Innominate artery, Supernumerary	Variation	15(5)				
Subclavian artery, left, Absent	Malformation				82(14)	
Subclavian artery, right, Absent	Malformation	21(10)				
<b>Reproductive Tract</b>						
Testis, left, Hemorrhagic	Malformation	18(2)	32(11), 40(9)		86(6), 87(2), 94(9)	
Testis, left, Malpositioned	Malformation		27(5)			

**Study Number:** R16011

**Test Type:** Teratology

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**R13: Fetal Defect Cross Reference Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 08/28/2019

**Time Report Requested:** 11:32:41

**Lab:** Southern Research

---

**F0 Female**

---

**Treatment Groups (mg/kg/day)**

---

		<b>0</b>	<b>62.5</b>	<b>125</b>	<b>250</b>	<b>500</b>
Testis, right, Hemorrhagic	Malformation		41(2)			
<b>Urinary Tract</b>						
Kidney, bilateral, Hydronephrosis	Malformation		33(3)			
Kidney, renal capsule, Misshapen	Malformation					113(2)
Ureter, left, Dilated	Variation	24(2)				

---

**Head**

---

<b>No. Fetuses Examined</b>	<b>163</b>	<b>147</b>	<b>148</b>	<b>138</b>	<b>163</b>
<b>No. Dams Examined</b>	<b>23</b>	<b>20</b>	<b>21</b>	<b>20</b>	<b>22</b>

Study Number: R16011

Test Type: Teratology

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

R13: Fetal Defect Cross Reference Summary  
Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine  
CAS Number: 95737-68-1

Date Report Requested: 08/28/2019

Time Report Requested: 11:32:41

Lab: Southern Research

---

F0 Female

---

Treatment Groups (mg/kg/day)

---

0                      62.5                      125                      250                      500

---

Skeletal - Body

---

<b>No. Fetuses Examined</b>	<b>314</b>	<b>286</b>	<b>290</b>	<b>265</b>	<b>318</b>
<b>No. Dams Examined</b>	<b>23</b>	<b>20</b>	<b>21</b>	<b>20</b>	<b>22</b>

**Axial Skeleton**

General, Not examined				79(13)	114(10)
-----------------------	--	--	--	--------	---------

**Forelimb**

Metacarpal, Unossified	Variation				125(10)
------------------------	-----------	--	--	--	---------

**Hindlimb**

Metatarsal, Unossified	Variation				125(10)
------------------------	-----------	--	--	--	---------

**Ribs**

Costal cartilage, 7th left, Not fused to sternum	Malformation	46(10)			
Costal cartilage, 7th right, Not fused to sternum	Malformation		57(8)		
Rib, 13th bilateral, Not examined					114(10,10)

**Sternebrae**

Study Number: R16011

Test Type: Teratology

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

R13: Fetal Defect Cross Reference Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 08/28/2019

Time Report Requested: 11:32:41

Lab: Southern Research

F0 Female

Treatment Groups (mg/kg/day)

		0	62.5	125	250	500
Sternebra, between sternebra, Variation			46(9)	71(5)		104(5,16), 120(8)
Supernumerary site					79(13,13)	
Xiphoid cartilage, Not examined						
<b>Supernumerary Rib</b>						
Thoracolumbar, bilateral, Full	Malformation	7(1), 14(5)	27(6)			125(10)
Thoracolumbar, bilateral, Short	Variation	10(5)	31(5), 32(5), 35(4)		99(12)	
Thoracolumbar, left, Full	Malformation	2(12), 5(15), 6(13,14)	31(1), 43(3)			
Thoracolumbar, left, Short	Variation	6(11), 7(4), 10(10), 25(7)	27(7), 32(12), 35(15), 41(6)	53(12), 59(9), 73(8)	83(7), 86(2,4,5), 99(5)	120(12,13), 125(12)
Thoracolumbar, right, Full	Malformation	6(11)		62(8)		
Thoracolumbar, right, Short	Variation	6(1,14), 10(4,16), 12(12), 18(5)	27(3), 30(7), 31(1,6,7), 37(9,10), 43(14), 49(15)	55(11), 57(1), 73(5)	99(4)	102(1), 111(10), 114(14)
<b>Vertebrae</b>						
Cervical vertebra, 4th, Misshapen	Malformation	8(2)				
Cervical vertebra, 5th, Misshapen	Malformation	9(6), 16(13), 21(1), 23(12), 24(9,11), 25(2)	35(14), 43(8), 49(10), 50(13)	58(12), 71(7)		
Cervical vertebra, 6th, Misshapen	Malformation	9(6), 16(13), 21(1), 23(12), 24(9,11), 25(2)	35(14), 43(8), 49(10), 50(13)	58(12)		
Presacral vertebrae, Greater than 26	Variation	7(1)				

**Study Number:** R16011

**Test Type:** Teratology

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**R13: Fetal Defect Cross Reference Summary**  
**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine  
**CAS Number:** 95737-68-1

**Date Report Requested:** 08/28/2019

**Time Report Requested:** 11:32:41

**Lab:** Southern Research

---

**F0 Female**

---

**Treatment Groups (mg/kg/day)**

---

		<b>0</b>	<b>62.5</b>	<b>125</b>	<b>250</b>	<b>500</b>
Thoracic centrum, 10th, Incomplete ossification	Variation	24(15)				
Thoracic centrum, 12th, Hemicentric	Variation				96(3)	
Thoracic centrum, 13th, Hemicentric	Variation				96(3)	
Thoracic centrum, 1st, Incomplete ossification	Variation	8(9)				
Thoracic centrum, multiple sites, Absent	Malformation				96(3)	

---

**Skeletal - Skull**

---

<b>No. Fetuses Examined</b>		<b>151</b>	<b>138</b>	<b>142</b>	<b>126</b>	<b>154</b>
<b>No. Dams Examined</b>		<b>23</b>	<b>20</b>	<b>20</b>	<b>20</b>	<b>22</b>
<b>Skull</b>						
General, Enlarged fontanel	Variation	3(10)				
General, Isolated ossification site	Variation				84(6)	102(12), 122(10)
General, Supernumerary site	Variation	4(4)			84(12)	
Interparietal, Incomplete ossification	Variation					114(10)
Interparietal, Isolated ossification site	Variation				76(10)	
Supraoccipital, Incomplete ossification	Variation					125(10)



**Study Number:** R16011

**Test Type:** Teratology

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**R13: Fetal Defect Cross Reference Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 08/28/2019

**Time Report Requested:** 11:32:41

**Lab:** Southern Research

---

**F0 Female**

---

**Treatment Groups (mg/kg/day)**

---

**0                      62.5                      125                      250                      500**

---

**Placental**

---

**No. Fetuses Examined                      314                      286                      290                      265                      318**

**No. Dams Examined                      23                      20                      21                      20                      22**

**Placentae**

Placenta, Large                      Gross Finding                      43(15)

---

**Study Number:** R16011

**Test Type:** Teratology

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**R13: Fetal Defect Cross Reference Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 08/28/2019

**Time Report Requested:** 11:32:41

**Lab:** Southern Research

LEGEND

---

Findings are reported by dam ID number (fetal ID number)

**\*\* END OF REPORT \*\***